Diabetic dyslipidaemia: from basic research to clinical practice*

Taskinen, M.-R.

doi:10.1007/s00125-003-1111-y

Cited by 888Lipid metabolism and disordersDiabetes, Cardiovascular Risks, and LipoproteinsLipoproteins and Cardiovascular Health

Diabetic dyslipidaemia: from basic research to clinical practice*

Open access

Taskinen, M.-R.·2003·Diabetologia

DOI 10.1007/s00125-003-1111-y

Open this paper in CoChat — free account Open PDF

Abstract

The recognition that the increase of plasma triglyceride rich lipoproteins (TRLs) is associated with multiple alterations of other lipoproteins species that are potentially atherogenic has expanded the picture of diabetic dyslipidaemia. The discovery of heterogeneity within major lipoprotein classes VLDL, LDL and HDL opened new avenues to reveal the specific pertubations of diabetic dyslipidaemia. The increase of large VLDL 1 particles in Type 2 diabetes initiates a sequence of events that generates atherogenic remnants, small dense LDL and small dense HDL particles. Together these components comprise the atherogenic lipid triad. Notably the malignant nature of diabetic dyslipidaemia is not completely shown by the lipid measures used in clinical practice. The key question is what are the mechanisms behind the increase of VLDL 1 particles in diabetic dyslipidaemia? Despite the advances of recent years, our understanding of VLDL assembly and secretion is still surprisingly incomplete. To date it is still unclear how the liver is able to regulate the amount of triglycerides incorporated into VLDL particles to produce either VLDL 1 or VLDL 2 particles. The current evidence suggests that the machinery driving VLDL assembly in the liver includes (i) low insulin signalling via PI-3 kinase pathway that enhances lipid accumulation into "nascent " VLDL particles (ii) up-regulation of SREBP-1C that stimulates de novo lipogenesis and (iii) excess availability of "polar molecules" in hepatocytes that stabilizes apo B 100. Recent data suggest that all these steps could be fundamentally altered in Type 2 diabetes explaining the overproduction of VLDL apo B as well as the ability of insulin to suppress VLDL 1 apo B production in Type 2 diabetes. Recent discoveries have established the transcription factors including PPARs, SREBP-1 and LXRs as the key regulators of lipid assembly in the liver. These observations suggest these factors as a new target to tailor more efficient drugs to treat diabetic dyslipidaemia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s00125-003-1111-y

Cites

183 of 183 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Multiple lipoprotein metabolism disturbances in prediabetes and type 2 diabetes arise from the combined effects of insulin deficiency, insulin resistance, and hyperglycemia.
“Multiple disturbances in lipoprotein metabolism in individuals with prediabetes and T2D result from the combined effects of insulin deficiency, insulin resistance, and hyperglycemia.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [305]
The sections on VLDL regulation and postprandial lipemia describe multiple lipoprotein disturbances in type 2 diabetes and link them to impaired insulin action and insulin resistance. They do not establish that the disturbances in both prediabetes and type 2 diabetes result from the combined effects of insulin deficiency, insulin resistance, and hyperglycemia. Page numbers are unavailable in our copy. (LLM, conf=0.86)
Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Magnesium Replacement Improves the Metabolic Profile in Obese and Pre-Diabetic Patients with Mild-to-Moderate Chronic Kidney Disease: A 3-Month, Randomised, Double-Blind, Placebo-Controlled Study
Toprak, Ö., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney & Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,769 · see citing works
Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944 · see citing works
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011 · see citing works
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198 · see citing works
Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000 · see citing works
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992 · see citing works
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883 · see citing works
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760 · see citing works
Self-citation
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581 · see citing works
Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23)
Turner, R. C., Millns, H., Neil, H. A. W., Stratton, I. M., Manley, S. E., Matthews, D. R., & Holman, R. R. (1998) · BMJ · doi:10.1136/bmj.316.7134.823 · Cited by 2,014 · see citing works
Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction
Austin, M. A. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410130125037 · Cited by 1,780 · see citing works
Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
Pyörälä, K., Pedersen, T. R., Kjekshus, J., Faergeman, O., Olsson, A. G., Thorgeirsson, G., & The Scandinavian Simvastatin Survival Study (4S) Group (1997) · Diabetes Care · doi:10.2337/diacare.20.4.614 · Cited by 1,623 · cited 1× · see citing works
“Landmark secondary prevention studies (4S, CARE, LIPID) have provided strong evidence of the clinical benefits of LDL-lowering in people with diabetes [157, 158, 159].”
Background
Glucose Tolerance and Cardiovascular Mortality: Comparison of Fasting and 2-Hour Diagnostic Criteria
(2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.3.397 · Cited by 1,371 · see citing works
Insulin resistance and cardiovascular disease
Ginsberg, H. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10762 · Cited by 1,358 · see citing works
Disordered Fat Storage and Mobilization in the Pathogenesis of Insulin Resistance and Type 2 Diabetes
Lewis, G. F., Carpentier, A. C., Adeli, K., & Giacca, A. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.2.0461 · Cited by 1,328 · see citing works
PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
Chinetti, G., Lestavel, S., Bocher, V., Remaley, A. T., Neve, B., Torra, I. P., Teissier, E., Minnich, A., Jaye, M., Duverger, N., et al. (2001) · Nature Medicine · doi:10.1038/83348 · Cited by 1,170 · see citing works
Small, Dense Low-Density Lipoprotein Particles as a Predictor of the Risk of Ischemic Heart Disease in Men: Prospective Results From the Que´bec Cardiovascular Study
Lamarche, B., Tchernof, A., Moorjani, S., Cantin, B., Dagenais, G. R., Lupien, P. J., & Despre´s, J.-P. (1997) · Circulation · doi:10.1161/01.cir.95.1.69 · Cited by 1,077 · see citing works
Subendothelial retention of atherogenic lipoproteins in early atherosclerosis
Skålén, K., Gustafsson, M., Rydberg, E. K., Hultén, L. M., Wiklund, O., Innerarity, T. L., & Borén, J. (2002) · Nature · doi:10.1038/nature00804 · Cited by 1,019 · see citing works
Cardiovascular Events and Their Reduction With Pravastatin in Diabetic and Glucose-Intolerant Myocardial Infarction Survivors With Average Cholesterol Levels: Subgroup Analyses in the Cholesterol And Recurrent Events (CARE) Trial
Goldberg, R. B., Mellies, M. J., Sacks, F. M., Moyé, L. A., Howard, B. V., Howard, W. J., Davis, B. R., Cole, T. G., Pfeffer, M. A., & Braunwald, E. (1998) · Circulation · doi:10.1161/01.cir.98.23.2513 · Cited by 986 · see citing works
Decreased IRS-2 and Increased SREBP-1c Lead to Mixed Insulin Resistance and Sensitivity in Livers of Lipodystrophic and ob/ob Mice
Shimomura, I., Matsuda, M., Hammer, R. E., Bashmakov, Y. K., Brown, M. S., & Goldstein, J. L. (2000) · Molecular Cell · doi:10.1016/s1097-2765(05)00010-9 · Cited by 847 · see citing works
Association of Small Low-Density Lipoprotein Particles With the Incidence of Coronary Artery Disease in Men and Women
Gardner, C. D. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540110029028 · Cited by 843 · cited 11× · see citing works
“Adult Treatment panel III (ATP III) designated diabetes as a CHD risk equivalent and LDL was identified the first priority of lipid lowering [6].”
BackgroundInfluential
Management of Dyslipidemia in Adults With Diabetes
Haffner, S. M. (1998) · Diabetes Care · doi:10.2337/diacare.21.1.160 · Cited by 786 · see citing works
Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial Infarction
Malmberg, K., Yusuf, S., Gerstein, H. C., Brown, J., Zhao, F., Hunt, D. U., Piegas, L. S., Calvin, J. E., Keltai, M., Budaj, A., et al. (2000) · Circulation · doi:10.1161/01.cir.102.9.1014 · Cited by 746 · see citing works
Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study
Steiner, G. A. (2001) · Cited by 732 · see citing works
Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects.
Graaf, J. D., Hak-Lemmers, H. L. M., Hectors, M. P. C., Demacker, P. N. M., Hendriks, J. C. M., & Stalenhoef, A. F. H. (1991) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.11.2.298 · Cited by 714 · see citing works
High Density Lipoproteins and Arteriosclerosis
von Eckardstein, A., Nofer, J., & Assmann, G. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.21.1.13 · Cited by 696 · see citing works
Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E
Mahley, R. W., & Ji, Z.-S. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33334-4 · Cited by 693 · see citing works
Impact of Diabetes on Mortality After the First Myocardial Infarction
Miettinen, H., Lehto, S., Salomaa, V., Mähönen, M., Niemelä, M., Haffner, S. M., Pyörälä, K., Tuomilehto, J., & The FINMONICA Myocardial Infarction Register Study Group (1998) · Diabetes Care · doi:10.2337/diacare.21.1.69 · Cited by 665 · see citing works
Evidence for an Independent and Cumulative Effect of Postprandial Hypertriglyceridemia and Hyperglycemia on Endothelial Dysfunction and Oxidative Stress Generation: Effects of Short- and Long-Term Simvastatin Treatment
Ceriello, A., Taboga, C., Tonutti, L., Quagliaro, L., Piconi, L., Bais, B., Da Ros, R., & Motz, E. (2002) · Circulation · doi:10.1161/01.cir.0000027569.76671.a8 · Cited by 655 · see citing works
Diabetic Dyslipidemia: Causes and Consequences
Goldberg, I. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.3.7304 · Cited by 648 · see citing works
The Effects of Rosiglitazone on Insulin Sensitivity, Lipolysis, and Hepatic and Skeletal Muscle Triglyceride Content in Patients With Type 2 Diabetes
Mayerson, A. B., Hundal, R. S., Dufour, S., Lebon, V., Befroy, D., Cline, G. W., Enocksson, S., Inzucchi, S. E., Shulman, G. I., & Petersen, K. F. (2002) · Diabetes · doi:10.2337/diabetes.51.3.797 · Cited by 647 · see citing works
Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study
de Vegt, F., Dekker, J. M., Ruhé, H. G., Stehouwer, C. D. A., Nijpels, G., Bouter, L. M., & Heine, R. J. (1999) · Diabetologia · doi:10.1007/s001250051249 · Cited by 611 · see citing works
Diabetes, Plasma Insulin, and Cardiovascular Disease: Subgroup Analysis From the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT)
Rubins, H. B. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.22.2597 · Cited by 586 · see citing works
[24] Nondenaturing polyacrylamide gradient gel electrophoresis
Nichols, A. V., Krauss, R. M., & Musliner, T. A. (1986) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(86)28084-2 · Cited by 522 · see citing works
VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial
Sacks, F. M., Alaupovic, P., Moye, L. A., Cole, T. G., Sussex, B., Stampfer, M. J., Pfeffer, M. A., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.102.16.1886 · Cited by 490 · see citing works
New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c
Foufelle, F., & Ferré, P. (2002) · Biochemical Journal · doi:10.1042/bj20020430 · Cited by 479 · see citing works
Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size
Tribble, D. L., Holl, L. G., Wood, P. D., & Krauss, R. M. (1992) · Atherosclerosis · doi:10.1016/0021-9150(92)90255-f · Cited by 468 · see citing works
Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients.
Ryysy, L., Häkkinen, A. M., Goto, T., Vehkavaara, S., Westerbacka, J., Halavaara, J., & Yki-Järvinen, H. (2000) · Diabetes · doi:10.2337/diabetes.49.5.749 · Cited by 431 · see citing works
Peroxisome proliterator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis
Fruchart, J.-C., Duriez, P., & Staels, B. (1999) · Current Opinion in Lipidology · doi:10.1097/00041433-199906000-00007 · Cited by 425 · see citing works
Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III.
Wang, C. S., McConathy, W. J., Kloer, H. U., & Alaupovic, P. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111711 · Cited by 414 · see citing works
Lipoprotein Heterogeneity and Apolipoprotein B Metabolism
Packard, C. J., & Shepherd, J. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.12.3542 · Cited by 401 · see citing works
Absence of Sterol Regulatory Element-binding Protein-1 (SREBP-1) Ameliorates Fatty Livers but Not Obesity or Insulin Resistance in Lep/Lep Mice
Yahagi, N., Shimano, H., Hasty, A. H., Matsuzaka, T., Ide, T., Yoshikawa, T., Amemiya-Kudo, M., Tomita, S., Okazaki, H., Tamura, Y., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201584200 · Cited by 370 · see citing works
Mechanisms of Hepatic Very Low Density Lipoprotein Overproduction in Insulin Resistance
Taghibiglou, C., Carpentier, A. C., Iderstine, S. C. V., Chen, B., Rudy, D., Aiton, A., Lewis, G. F., & Adeli, K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.8416 · Cited by 346 · see citing works
Hypertriglyceridemic HyperapoB: The Unappreciated Atherogenic Dyslipoproteinemia in Type 2 Diabetes Mellitus
Sniderman, A. D., Scantlebury, T., & Cianflone, K. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-6-200109180-00014 · Cited by 329 · see citing works
Effects of Acute Hyperinsulinemia on VLDL Triglyceride and VLDL ApoB Production in Normal Weight and Obese Individuals
Lewis, G. F., Uffelman, K. D., Szeto, L., & Steiner, G. A. (1993) · Diabetes · doi:10.2337/diab.42.6.833 · Cited by 323 · see citing works
The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men
Tchernof, A., Lamarche, B., Prud'homme, D., Nadeau, A., Moorjani, S., Labrie, F., Lupien, P. J., & Després, J.-P. (1996) · Diabetes Care · doi:10.2337/diacare.19.6.629 · Cited by 323 · see citing works
Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM.
Malmström, R., Packard, C. J., Caslake, M., Bedford, D., Stewart, P., Yki-Järvinen, H., Shepherd, J., & Taskinen, M.-R. (1997) · Diabetologia · doi:10.1007/s001250050700 · Cited by 319 · see citing works
Self-citation
Pleiotropic Effects of Statins: Lipid Reduction and Beyond
McFarlane, S. I., Muniyappa, R., Francisco, R., & Sowers, J. R. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.4.8412 · Cited by 315 · see citing works
LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes.
Feingold, K. R., Grünfeld, C., Pang, M., Doerrler, W. T., & Krauss, R. M. (1992) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.12.12.1496 · Cited by 302 · see citing works
Mobilisation of triacylglycerol stores
Gibbons, G. F., Islam, K., & Pease, R. J. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(99)00182-1 · Cited by 298 · see citing works
Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women
Coresh, J., Kwiterovich, P., Smith, H., & Bachorik, P. S. (1993) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)35731-x · Cited by 290 · see citing works
Metabolic and Additional Vascular Effects of Thiazolidinediones
Martens, F. M. A. C., Visseren, F. L. J., Lemay, J., de Koning, E. J. P., & Rabelink, T. J. (2002) · Drugs · doi:10.2165/00003495-200262100-00004 · Cited by 289 · see citing works
Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism
Shachter, N. S. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200106000-00009 · Cited by 288 · see citing works
Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway.
Sehayek, E., & Eisenberg, S. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55263-7 · Cited by 283 · see citing works
Lipoprotein lipase in diabetes
Taskinen, M. (1987) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610030208 · Cited by 273 · see citing works
Self-citation
Relationships Between Low-Density Lipoprotein Particle Size, Plasma Lipoproteins, and Progression of Coronary Artery Disease
Vakkilainen, J., Steiner, G. A., Ansquer, J.-C., Aubin, F., Rattier, S., Foucher, C., Hamsten, A., & Taskinen, M. (2003) · Circulation · doi:10.1161/01.cir.0000057982.50167.6e · Cited by 270 · see citing works
Self-citation
Fasting and Postprandial Overproduction of Intestinally Derived Lipoproteins in an Animal Model of Insulin Resistance
Haidari, M., Leung, N. M., Mahbub, F., Uffelman, K. D., Avramoglu, R. K., Lewis, G. F., & Adeli, K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200544200 · Cited by 269 · see citing works
Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus
Syvänne, M., & Taskinen, M. (1997) · The Lancet · doi:10.1016/s0140-6736(97)90024-6 · Cited by 268 · see citing works
Self-citation
Beyond lipid lowering: the role of statins in vascular protection
Liao, J. K. (2002) · International Journal of Cardiology · doi:10.1016/s0167-5273(02)00195-x · Cited by 261 · see citing works
Measurement issues related to lipoprotein heterogeneity
Otvos, J. D., Jeyarajah, E. J., & Cromwell, W. C. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02632-2 · Cited by 259 · see citing works
Comparison of Various Electrophoretic Characteristics of LDL Particles and Their Relationship to the Risk of Ischemic Heart Disease
St-Pierre, A., Ruel, I. L., Cantin, B., Dagenais, G. R., Bernard, P., Després, J., & Lamarche, B. (2001) · Circulation · doi:10.1161/hc4401.098490 · Cited by 259 · see citing works
Proatherogenic Role of Elevated CE Transfer From HDL to VLDL 1 and Dense LDL in Type 2 Diabetes
Guérin, M., Goff, W. L., Lassel, T. S., van Tol, A., Steiner, G. A., & Chapman, M. J. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.21.2.282 · Cited by 258 · see citing works
Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans.
Schneeman, B. O., Kotite, L., Todd, K., & Havel, R. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.2069 · Cited by 255 · see citing works
New Perspectives on Atherogenesis: Role of Abnormal Triglyceride-Rich Lipoprotein Metabolism
Ginsberg, H. N. (2002) · Circulation · doi:10.1161/01.cir.0000035280.64322.31 · Cited by 255 · see citing works
Increased ABCA1 activity protects against atherosclerosis
Singaraja, R. R., Fievet, C., Castro, G., James, E. R., Hennuyer, N., Clee, S. M., Bissada, N., Choy, J. C., Fruchart, J.-C., McManus, B. M., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15748 · Cited by 250 · see citing works
Pyridoxamine, an Inhibitor of Advanced Glycation Reactions, Also Inhibits Advanced Lipoxidation Reactions
Onorato, J. M., Jenkins, A. J., Thorpe, S. R., & Baynes, J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003263200 · Cited by 250 · see citing works
The role of PPARs in atherosclerosis
Duval, C., Chinetti, G., Trottein, F., Fruchart, J., & Staels, B. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02385-7 · Cited by 246 · see citing works
Impact of Diabetes on Long-Term Survival After Acute Myocardial Infarction
Mukamal, K. J., Nesto, R. W., Cohen, M. C., Muller, J. E., Maclure, M., Sherwood, J. B., & Mittleman, M. A. (2001) · Diabetes Care · doi:10.2337/diacare.24.8.1422 · Cited by 245 · see citing works
Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions
Packard, C. J., Demant, T., Stewart, J., Bedford, D. K., CASLAKE, M. J., Schwertfeger, G., Bedynek, A., Shepherd, J., & Seidel, D. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32065-4 · Cited by 240 · see citing works
Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans
Anber, V., Griffin, B. A., McConnell, M., Packard, C. J., & Shepherd, J. (1996) · Atherosclerosis · doi:10.1016/0021-9150(96)05842-x · Cited by 237 · see citing works
Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100.
Borén, J., Lee, I., Zhu, W., Arnold, K. S., Taylor, S., & Innerarity, T. L. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1847 · Cited by 233 · see citing works
Lipoprotein glycation and its metabolic consequences
Lyons, T. J., & Jenkins, A. J. (1997) · Current Opinion in Lipidology · doi:10.1097/00041433-199706000-00008 · Cited by 232 · see citing works
Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men
Lamarche, B., Uffelman, K. D., Carpentier, A. C., Cohn, J. S., Steiner, G., Barrett, P. H. R., & Lewis, G. F. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5286 · Cited by 230 · see citing works
Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity
Galeano, N. F., Al-Haideri, M. T., Keyserman, F., Rumsey, S. C., & Deckelbaum, R. J. (1998) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32551-7 · Cited by 229 · see citing works
Remnant Lipoproteins Induce Proatherothrombogenic Molecules in Endothelial Cells Through a Redox-Sensitive Mechanism
Doi, H., Kugiyama, K., Oka, H., Sugiyama, S., Ogata, N., Koide, S.-I., Nakamura, S.-I., & Yasue, H. (2000) · Circulation · doi:10.1161/01.cir.102.6.670 · Cited by 227 · see citing works
Ciprofibrate Therapy Improves Endothelial Function and Reduces Postprandial Lipemia and Oxidative Stress in Type 2 Diabetes Mellitus
Evans, M., Anderson, R. A., Graham, J. J., Ellis, G. R., Morris, K., Davies, S., Jackson, S. K., LEWIS, M. J., Frenneaux, M. P., & Rees, A. (2000) · Circulation · doi:10.1161/01.cir.101.15.1773 · Cited by 225 · see citing works
Acute Elevations of Plasma Asymmetric Dimethylarginine and Impaired Endothelial Function in Response to a High-Fat Meal in Patients With Type 2 Diabetes
Fard, A., Tuck, C. H., Donis, J. A., Sciacca, R. R., Tullio, M. R. D., Wu, H. D., Bryant, T. A., Chen, N.-T., Torres‐Tamayo, M., Ramasamy, R., et al. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.9.2039 · Cited by 221 · see citing works
Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion
Sparks, J. D., & Sparks, C. E. (1994) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(94)90088-4 · Cited by 217 · see citing works
Management of Dyslipidemia in Adults With Diabetes
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s83 · Cited by 206 · see citing works
Coronary Heart Disease in Patients With Low LDL-Cholesterol: Benefit of Pravastatin in Diabetics and Enhanced Role for HDL-Cholesterol and Triglycerides as Risk Factors
Sacks, F., Tonkin, A., Craven, T., Pfeffer, M., Shepherd, J., Keech, A., Furberg, C., & Braunwald, E. (2002) · Circulation · doi:10.1161/01.cir.0000012918.84068.43 · Cited by 198 · see citing works
Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects.
Malmström, R., Packard, C. J., CASLAKE, M. J., Bedford, D. K., Stewart, P., Yki‐Järvinen, H., Shepherd, J., & Taskinen, M. (1998) · Diabetes · doi:10.2337/diabetes.47.5.779 · Cited by 197 · see citing works
Self-citation
Microsomal triglyceride transfer protein (MTP) regulation in HepG2 cells: insulin negatively regulates MTP gene expression.
Lin, M., Gordon, D., & Wetterau, J. R. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39865-5 · Cited by 196 · see citing works
Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E.
Ebara, T., Ramakrishnan, R., Steiner, G. A., & Shachter, N. S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119456 · Cited by 191 · see citing works
Integrated Regulation of Very Low Density Lipoprotein Triglyceride and Apolipoprotein-B Kinetics in Non-insulin-dependent Diabetes Mellitus
Kissebah, A. H., Alfarsi, S., Evans, D. J., & ADAMS, P. W. (1982) · Diabetes · doi:10.2337/diab.31.3.217 · Cited by 190 · see citing works
Effects of native and oxidized low density lipoproteins on formation and inactivation of endothelium-derived relaxing factor.
Galle, J., Mülsch, A., Busse, R., & Bassenge, E. (1991) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.11.1.198 · Cited by 185 · see citing works
Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity
Pascot, A., Lemieux, I., Prud’homme, D., Tremblay, A., Nadeau, A., Couillard, C., Bergeron, J., Lamarche, B., & Després, J. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31529-7 · Cited by 184 · see citing works
HDL metabolism in hypertriglyceridemic states: an overview
Lamarche, B., Rashid, S., & Lewis, G. F. (1999) · Clinica Chimica Acta · doi:10.1016/s0009-8981(99)00098-4 · Cited by 184 · see citing works
Apoprotein B structure and receptor recognition of triglyceride-rich low density lipoprotein (LDL) is modified in small LDL but not in triglyceride-rich LDL of normal size.
Galeano, N. F., Milne, R. W., Marcel, Y. L., Walsh, M. T., Levy, E. H., Ngu'yen, T. D., Gleeson, A. M., Arad, Y., Witte, L., & Al-Haideri, M. T. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42379-9 · Cited by 181 · see citing works
Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches.
Chapman, M. J., Guérin, M., & Bruckert, É. (1998) · PubMed · Cited by 178 · see citing works
Metabolic Basis of Hypotriglyceridemic Effects of Insulin in Normal Men
Malmström, R., Packard, C. J., Watson, T. D. G., Rannikko, S., CASLAKE, M. J., Bedford, D. K., Stewart, P., Yki‐Järvinen, H., Shepherd, J., & Taskinen, M. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.7.1454 · Cited by 178 · see citing works
Self-citation
Fat Accumulation in the Liver Is Associated with Defects in Insulin Suppression of Glucose Production and Serum Free Fatty Acids Independent of Obesity in Normal Men
Seppala-Lindroos, A. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.7.3023 · Cited by 168 · see citing works
Effects of NIDDM on Very-Low-Density Lipoprotein Triglyceride and Apolipoprotein B Metabolism: Studies Before and After Sulfonylurea Therapy
Taskinen, M., Beltz, W. F., Harper, I., Fields, R. M., Schonfeld, G., Grundy, S. M., & Howard, B. V. (1986) · Diabetes · doi:10.2337/diab.35.11.1268 · Cited by 159 · see citing works
Self-citation
Impaired endothelium-dependent vasodilation in type 2 diabetes. Relation to LDL size, oxidized LDL, and antioxidants.
Mäkimattila, S., Liu, M., Vakkilainen, J., Schlenzka, A., Lahdenperä, S., Syvänne, M., Mäntysaari, M., Summanen, P. A., Bergholm, R., Taskinen, M., et al. (1999) · Diabetes Care · doi:10.2337/diacare.22.6.973 · Cited by 156 · see citing works
Self-citation
High Density Lipoprotein (HDL) Metabolism in Noninsulin-Dependent Diabetes Mellitus: Measurement of HDL Turnover Using Tritiated HDL*
Golay, A., Zech, L. A., SHI, M.-Z., Chiou, Y.-A. M., Reaven, G. M., & Chen, Y. I. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-65-3-512 · Cited by 154 · see citing works
Specific Impairment of Endothelium-Dependent Vasodilation in Subjects with Type 2 Diabetes Independent of Obesity
Hogikyan, R. V., Gałecki, A. T., Pitt, B., Halter, J. B., Greene, D. A., & Supiano, M. A. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.6.4907 · Cited by 149 · see citing works
Peroxisome-proliferator-activated receptor-α (PPARα) deficiency leads to dysregulation of hepatic lipid and carbohydrate metabolism by fatty acids and insulin
Sugden, M. C., Bulmer, K., Gibbons, G. F., Knight, B. L., & Holness, M. J. (2002) · Biochemical Journal · doi:10.1042/bj20011699 · Cited by 149 · see citing works
Beyond postprandial hyperglycaemia: metabolic factors associated with cardiovascular disease
Heine, R. J., & Dekker, J. M. (2002) · Diabetologia · doi:10.1007/s00125-001-0726-0 · Cited by 146 · see citing works
Intracellular Assembly of VLDL
Olofsson, S., Stillemark-Billton, P., & Asp, L. (2000) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(01)00071-8 · Cited by 145 · see citing works
Quantification of postprandial triglyceride-rich lipoproteins in healthy men by retinyl ester labeling and simultaneous measurement of apolipoproteins B-48 and B-100
Karpe, F., Bell, M., Björkegren, J., & Hamsten, A. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.2.199 · Cited by 143 · see citing works
Role of the Insulin Receptor Substrate 1 and Phosphatidylinositol 3-Kinase Signaling Pathway in Insulin-Induced Expression of Sterol Regulatory Element Binding Protein 1c and Glucokinase Genes in Rat Hepatocytes
Matsumoto, M., Ogawa, W., Teshigawara, K., Inoue, H., Miyake, K., Sakaue, H., & Kasuga, M. (2002) · Diabetes · doi:10.2337/diabetes.51.6.1672 · Cited by 138 · see citing works
Insulin resistance affects the regulation of lipoprotein lipase in the postprandial period and in an adipose tissue‐specific manner
Panarotto, D., Rémillard, P., Bouffard, L., & Maheux, P. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2002.00945.x · Cited by 137 · see citing works
Relations Between Plasma Lipids and Postheparin Plasma Lipases and VLDL and LDL Subfraction Patterns in Normolipemic Men and Women
Tan, C., Forster, L. F., CASLAKE, M. J., Bedford, D. K., Watson, T. D. G., McConnell, M., Packard, C. J., & Shepherd, J. (1995) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.15.11.1839 · Cited by 137 · see citing works
High density lipoprotein subfractions in non-insulin-dependent diabetes mellitus and coronary artery disease.
Syvänne, M., Ahola, M., Lahdenperä, S., Kahri, J., Kuusi, T., Virtanen, K. S., & Taskinen, M. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39891-6 · Cited by 133 · see citing works
Self-citation
Endothelial Dysfunction in Men With Small LDL Particles
Vakkilainen, J., Mäkimattila, S., Seppälä‐Lindroos, A., Vehkavaara, S., Lahdenperä, S., Groop, P., Taskinen, M., & Yki‐Järvinen, H. (2000) · Circulation · doi:10.1161/01.cir.102.7.716 · Cited by 133 · see citing works
Self-citation
U.K. Prospective Diabetes Study 27: Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex
U.K. Prospective Diabetes Study Group (1997) · Diabetes Care · doi:10.2337/diacare.20.11.1683 · Cited by 129 · see citing works
Role of insulin in hepatic fatty acid partitioning: emerging concepts
Zammit, V. A. (1996) · Biochemical Journal · doi:10.1042/bj3140001 · Cited by 125 · see citing works
Triglyceride‐rich lipoproteins in non‐insulin‐dependent diabetes mellitus: post‐prandial metabolism and relation to premature atherosclerosis
de Man, F. H. A. F., Cabezas, M. C., van Barlingen, H. H. J. J., Erkelens, D. W., & de Bruin, T. W. (1996) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1996.114256.x · Cited by 124 · see citing works
Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study
Duvillard, L., Pont, F., Florentin, E., Galland-Jos, C., Gambert, P., & Vergès, B. L. (2000) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2000.00755.x · Cited by 123 · see citing works
Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM
Cummings, M. H., Watts, G. F., Umpleby, A. M., Hennessy, T. R., Naoumova, R. P., Slavin, B. M., Thompson, G. R., & S�nksen, P. H. (1995) · Diabetologia · doi:10.1007/bf00400586 · Cited by 121 · see citing works
Phosphoinositide 3-Kinase Activity Is Necessary for Insulin-dependent Inhibition of Apolipoprotein B Secretion by Rat Hepatocytes and Localizes to the Endoplasmic Reticulum
Phung, T. L., Roncone, A. M., Jensen, K. L. D. M., Sparks, C. E., & Sparks, J. D. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.49.30693 · Cited by 121 · see citing works
Hepatic Expression of Microsomal Triglyceride Transfer Protein and In Vivo Secretion of Triglyceride-Rich Lipoproteins Are Increased in Obese Diabetic Mice
Bartels, E. D., Lauritsen, M. L., & Nielsen, L. B. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1233 · Cited by 120 · see citing works
Apolipoproteins C–III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Temoins sur 'Infarctus du Myocarde
Luc, G., Fievet, C., Arveiler, D., Evans, A. E., Bard, J. M., Cambien, F., Fruchart, J. C., & Ducimetiere, P. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37594-5 · Cited by 114 · see citing works
Analysis of plasma lipids and apolipoproteins in insulin-dependent and noninsulin-dependent diabetics
BRIONES, E. R., Mao, S. J. T., Palumbo, P. J., O’Fallon, W. M., CHENOWETH, W. L., & Kottke, B. A. (1984) · Metabolism · doi:10.1016/0026-0495(84)90160-4 · Cited by 107 · see citing works
Identification of the Proteoglycan Binding Site in Apolipoprotein B48
Flood, C., Gustafsson, M. V., Richardson, P. E., Harvey, S. C., Segrest, J. P., & Borén, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204053200 · Cited by 107 · see citing works
Hepatic steatosis and type 2 diabetes mellitus
Clark, J. M., & Diehl, A. M. (2002) · Current Diabetes Reports · doi:10.1007/s11892-002-0085-3 · Cited by 106 · see citing works
Relation of LDL Size to the Insulin Resistance Syndrome and Coronary Heart Disease in American Indians
Gray, R. S., Robbins, D. C., Wang, W., Yeh, J. L., Fabsitz, R. R., Cowan, L. D., Welty, T. K., Lee, E. T., Krauss, R. M., & Howard, B. V. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.11.2713 · Cited by 105 · see citing works
Cholesterol efflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: importance of LpA-I:A-II particles and phospholipid transfer protein
Syvänne, M., Castro, G., Dengremont, C., Geitere, C. D., Jauhiainen, M., Ehnholm, C., Michelagnoli, S., Franceschini, G., Kahri, J., & Taskinen, M. (1996) · Atherosclerosis · doi:10.1016/s0021-9150(96)05962-x · Cited by 105 · see citing works
Self-citation
A Tailored Therapy for the Metabolic Syndrome
Etgen, G. J., Oldham, B. A., Johnson, W. T., Broderick, C. L., Montrose, C., Brozinick, J. T., Misener, E. A., Bean, J. S., Bensch, W. R., Brooks, D. A., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1083 · Cited by 105 · see citing works
Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease: importance of serum triglycerides
Lahdenper, S., Syv�nne, M., Kahri, J., & Taskinen, M. (1996) · Diabetologia · doi:10.1007/bf00400677 · Cited by 103 · see citing works
Self-citation
Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice
Ebara, T., Conde, K., Kako, Y., Liu, Y., Xu, Y. K., Ramakrishnan, R., Goldberg, I. J., & Shachter, N. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8283 · Cited by 103 · see citing works
Effect of Insulin Therapy on Metabolic Fate of Apolipoprotein B–Containing Lipoproteins in NIDDM
Taskinen, M., Packard, C. J., & Shepherd, J. (1990) · Diabetes · doi:10.2337/diab.39.9.1017 · Cited by 103 · see citing works
Self-citation
Ectopic fat accumulation: an important cause of insulin resistance in humans.
Yki‐Järvinen, H. (2002) · Europe PMC (PubMed Central) · Cited by 102 · see citing works
The Role of Insulin Insensitivity and Hepatic Lipase in the Dyslipidaemia of Type 2 Diabetes
Baynes, C., Henderson, A. D., Anyaoku, V., Richmond, W., Hughes, C. L., Johnston, D. G., & Elkeles, R. S. (1991) · Diabetic Medicine · doi:10.1111/j.1464-5491.1991.tb01652.x · Cited by 98 · see citing works
Ameliorated Hepatic Insulin Resistance Is Associated with Normalization of Microsomal Triglyceride Transfer Protein Expression and Reduction in Very Low Density Lipoprotein Assembly and Secretion in the Fructose-fed Hamster
Carpentier, A. C., Taghibiglou, C., Leung, N. M., Szeto, L., Iderstine, S. C. V., Uffelman, K. D., Buckingham, R. E., Adeli, K., & Lewis, G. F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204568200 · Cited by 97 · see citing works
Abnormal metabolism of postprandial lipoproteins in patients with non-insulin-dependent diabetes mellitus is not related to coronary artery disease.
Syvänne, M., Hilden, H., & Taskinen, M. (1994) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)40121-x · Cited by 97 · see citing works
Self-citation
Lipolytically Modified Triglyceride-Enriched HDLs Are Rapidly Cleared From the Circulation
Rashid, S., Barrett, P. H. R., Uffelman, K. D., Watanabe, T., Adeli, K., & Lewis, G. F. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq0302.105374 · Cited by 96 · see citing works
Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus
Ginsberg, H. N., & Illingworth, D. R. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01831-8 · Cited by 94 · see citing works
Influence of Peroxisome Proliferator-activated Receptor α Agonists on the Intracellular Turnover and Secretion of Apolipoprotein (Apo) B-100 and ApoB-48
Lindén, D., Lindberg, K., Oscarsson, J., Claesson, C., Asp, L., Lu, L., Gustafsson, M. V., Borén, J., & Olofsson, S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110416200 · Cited by 92 · see citing works
Phospholipase A2 and small, dense low-density lipoprotein
Hurt‐Camejo, E., Camejo, G., & Sartipy, P. (2000) · Current Opinion in Lipidology · doi:10.1097/00041433-200010000-00004 · Cited by 90 · see citing works
Lipoprotein compositional abnormalities and insulin resistance in type II diabetic patients with mild hyperlipidemia.
Stewart, M. W., Laker, M. F., Dyer, R. G., Game, F. L., Mitcheson, J., Winocour, P. H., & Alberti, K. G. M. M. (1993) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.13.7.1046 · Cited by 89 · see citing works
Insulin Inhibits the Maturation Phase of VLDL Assembly via a Phosphoinositide 3-Kinase—Mediated Event
Brown, A.-M., & Gibbons, G. F. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq1001.096640 · Cited by 89 · see citing works
Enhanced expression of hepatic acyl-coenzyme A synthetase and microsomal triglyceride transfer protein messenger RNAs in the obese and hypertriglyceridemic rat with visceral fat accumulation
Kuriyama, H., Yamashita, S., Shimomura, I., Funahashi, T., Ishigami, M., Aragane, K., Miyaoka, K., Nakamura, T., Takemura, K., Man, Z., et al. (1998) · Hepatology · doi:10.1002/hep.510270233 · Cited by 88 · see citing works
Interaction of native and modified low-density lipoproteins with extracellular matrix
Chait, A., & Wight, T. N. (2000) · Current Opinion in Lipidology · doi:10.1097/00041433-200010000-00003 · Cited by 87 · see citing works
Glucose-stimulated insulin secretion suppresses hepatic triglyceride-rich lipoprotein and apoB production
Chirieac, D. V., Chirieac, L. R., Corsetti, J. P., Cianci, J., Sparks, C. E., & Sparks, J. D. (2000) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2000.279.5.e1003 · Cited by 87 · see citing works
In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance.
Pietzsch, J., Julius, U., Nitzsche, S., & Markolf Hanefeld, E. (1998) · Diabetes · doi:10.2337/diabetes.47.12.1928 · Cited by 86 · see citing works
Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in Type II diabetes
Gervaise, N., Garrigue, M. A., Lasfargues, G., & Lecomte, P. (2000) · Diabetologia · doi:10.1007/s001250051366 · Cited by 82 · see citing works
Influence of Low Density Lipoprotein (LDL) Subfraction Profile and LDL Oxidation on Endothelium-Dependent and Independent Vasodilation in Patients with Type 2 Diabetes
Tan, K. C. B., Ai, V. H. G., Chow, W.-S., Chau, M. T., Leong, L. L. Y., & Lam, K. S. L. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.9.5959 · Cited by 81 · see citing works
Chylomicron/chylomicron remnant turnover in humans: evidence for margination of chylomicrons and poor conversion of larger to smaller chylomicron remnants
Karpe, F., Olivecrona, T., Hamsten, A., & Hultin, M. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37219-9 · Cited by 80 · see citing works
Cholesteryl Ester Hydroperoxide Lability Is a Key Feature of the Oxidative Susceptibility of Small, Dense LDL
Chancharme, L., Thérond, P., Nigon, F., Lepage, S., Couturier, M., & Chapman, M. J. (1999) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.19.3.810 · Cited by 80 · see citing works
High density lipoprotein apolipoprotein AI kinetics in NIDDM: a stable isotope study
Frénais, R., Ouguerram, K., Maugeais, C., Mahot, P., Maugère, P., Krempf, M., & Magot, T. (1997) · Diabetologia · doi:10.1007/s001250050718 · Cited by 79 · see citing works
Optimization of Glycemic Control by Insulin Therapy Decreases the Proportion of Small Dense LDL Particles in Diabetic Patients
Caixàs, A., Ordóñez‐Llanos, J., de Leiva, A., Payés, A., Homs, R., & Pérez, A. (1997) · Diabetes · doi:10.2337/diab.46.7.1207 · Cited by 79 · see citing works
Role of extracellular retention of low density lipoproteins in atherosclerosis
Borén, J., Gustafsson, M. V., Skålén, K., Flood, C., & Innerarity, T. L. (2000) · Current Opinion in Lipidology · doi:10.1097/00041433-200010000-00002 · Cited by 75 · see citing works
Glucose Regulates the Transcription of Human Genes Relevant to HDL Metabolism
Tu, A.-Y., & Albers, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1851 · Cited by 75 · see citing works
Pleiotropic effects of statins: do they matter?
Gotto, A. M., & Farmer, J. A. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200108000-00004 · Cited by 74 · see citing works
Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia
Campos, H., Perlov, D., Khoo, C., & Sacks, F. M. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31574-1 · Cited by 73 · see citing works
Abnormalities in apo B-containing lipoproteins in diabetes and atherosclerosis
TOMKIN, G. H., & Owens, D. (2001) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.179 · Cited by 71 · see citing works
Remarkably high prevalence of small dense low-density lipoprotein in Japanese men with coronary artery disease, irrespective of the presence of diabetes
Koba, S., Hirano, T., Yoshino, G., Sakai, K., Sakaue, T., Adachi, M., & Katagiri, T. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00580-9 · Cited by 69 · see citing works
HDLs Containing Apolipoproteins A-I and A-II (LpA-I:A-II) as Markers of Coronary Artery Disease in Men With Non–Insulin- Dependent Diabetes Mellitus
Syvänne, M., Kahri, J., Virtanen, K. S., & Taskinen, M. (1995) · Circulation · doi:10.1161/01.cir.92.3.364 · Cited by 64 · see citing works
Self-citation
Apolipoprotein B metabolism in humans: studies with stable isotope-labeled amino acid precursors
Marsh, J. B., Welty, F. K., Lichtenstein, A. H., Lamon‐Fava, S., & Schaefer, E. J. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00709-2 · Cited by 63 · see citing works
Plasma phospholipid transfer protein activity is lowered by 24-h insulin and acipimox administration: blunted response to insulin in type 2 diabetic patients.
Riemens, S. C., van Tol, A., Sluiter, W. J., & Dullaart, R. P. F. (1999) · Diabetes · doi:10.2337/diabetes.48.8.1631 · Cited by 59 · see citing works
Very low density lipoprotein subfractions in Type II diabetes mellitus: alterations in composition and susceptibility to oxidation
McEneny, J., O’Kane, M., Moles, K. W., McMaster, C., McMaster, D., Mercer, C., Trimble, E. R., & Young, I. S. (2000) · Diabetologia · doi:10.1007/s001250051333 · Cited by 52 · see citing works
Pathogenesis of dyslipidemia in type 2 diabetes
Taskinen, M. (2001) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2001-18580 · Cited by 52 · see citing works
Self-citation
Significance of Hepatic Triglyceride Lipase Activity in the Regulation of Serum High Density Lipoproteins in Type II Diabetes Mellitus*
Kasim, S. E., Tseng, K. H., Jen, K. ‐. C., & Khilnani, S. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-65-1-183 · Cited by 50 · see citing works
Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes
Vakkilainen, J., Mero, N., Schweizer, A., Foley, J. E., & Taskinen, M. (2002) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.324 · Cited by 50 · see citing works
Self-citation
Composition of serum very-low-density and high-density lipoproteins in diabetes.
Gabor, J., Spain, M., & Kalant, N. (1980) · Clinical Chemistry · doi:10.1093/clinchem/26.9.1261 · Cited by 48 · see citing works
Lipoprotein correlates of LDL particle size
Rainwater, D. L. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(99)00216-6 · Cited by 48 · see citing works
LDL Size Distribution in Relation to Insulin Sensitivity and Lipoprotein Pattern in Young and Healthy Subjects
Ambrosch, A., Mühlen, I., Kopf, D., Augustus, W., Dierkes, J., König, W., Luley, C. H., & Lehnert, H. (1998) · Diabetes Care · doi:10.2337/diacare.21.12.2077 · Cited by 46 · see citing works
Differential Metabolism of Human VLDL According to Content of ApoE and ApoC-III
Tomiyasu, K., Walsh, B. W., Ikewaki, K., Judge, H., & Sacks, F. M. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq0901.094489 · Cited by 46 · see citing works
Responses to eating: lipoproteins, lipolytic products and atherosclerosis
Goldberg, I. J., Kako, Y., & Lutz, E. P. (2000) · Current Opinion in Lipidology · doi:10.1097/00041433-200006000-00003 · Cited by 46 · see citing works
LDL particle size in mildly hypertriglyceridemic subjects: no relation to insulin resistance or diabetes
Lahdenperä, S., Sane, T., Vuorinen-Markkola, H., Knudsen, P., & Taskinen, M. (1995) · Atherosclerosis · doi:10.1016/0021-9150(94)05450-w · Cited by 43 · see citing works
Self-citation
In VivoEvidence for the Role of Lipoprotein Lipase Activity in the Regulation of Apolipoprotein AI Metabolism: A Kinetic Study in Control Subjects and Patients with Type II Diabetes Mellitus1
Frénais, R., Nazih, H., Ouguerram, K., Maugeais, C., Zaïr, Y., Bard, J., Charbonnel, B. H., Magot, T., & Krempf, M. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.5.7480 · Cited by 43 · see citing works
Roles of hepatic lipase and cholesteryl ester transfer protein in determining low density lipoprotein subfraction distribution in Chinese patients with non-insulin-dependent diabetes mellitus
Tan, K. C. B., Shiu, S. W. M., & Chu, B. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)00077-5 · Cited by 42 · see citing works
Sensitivity to Acute Insulin-Mediated Suppression of Plasma Free Fatty Acids Is Not a Determinant of Fasting VLDL Triglyceride Secretion in Healthy Humans
Carpentier, A. C., Patterson, B. W., Leung, N. M., & Lewis, G. F. (2002) · Diabetes · doi:10.2337/diabetes.51.6.1867 · Cited by 41 · see citing works
Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials
Armitage, J., & Collins, R. (2000) · Heart · doi:10.1136/heart.84.4.357 · Cited by 41 · see citing works
Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM
Taskinen, M., Packard, C. J., & Shepherd, J. (1990) · Diabetes · doi:10.2337/diabetes.39.9.1017 · Cited by 40 · see citing works
Self-citation
Acute hyperinsulinemia and very-low-density and low-density lipoprotein subfractions in obese subjects
Bioletto, S., Golay, A., Munger, R., Kalix, B., & James, R. W. (2000) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.2.443 · Cited by 39 · see citing works
Coordination of very low-density lipoprotein triglyceride and apolipoprotein B metabolism in humans: Effects of obesity and non-insulin-dependent diabetes mellitus
Howard, B. V., Abbott, W. G. H., Egusa, G., & Taskinen, M. (1987) · American Heart Journal · doi:10.1016/0002-8703(87)90625-9 · Cited by 39 · see citing works
Self-citation
Delayed clearance of postprandial large TG-rich particles in normolipidemic carriers of LPL Asn291Ser gene variant
Mero, N., Suurinkeroinen, L., Syvänne, M., Knudsen, P., Yki‐Järvinen, H., & Taskinen, M. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33412-x · Cited by 38 · see citing works
Self-citation
Lipoprotein composition in NIDDM: effects of dietary oleic acid on the composition, oxidisability and function of low and high density lipoproteins
Dimitriadis, E., Griffin, M., Collins, P. B., Johnson, A., Owens, D., & TOMKIN, G. (1996) · Diabetologia · doi:10.1007/bf00418538 · Cited by 34 · see citing works
Reduced IGFBP-1 Is Associated With Thickening of the Carotid Wall in Type 2 Diabetes
Leinonen, E. S., Salonen, J. T., Salonen, R. M., Koistinen, R. A., Leinonen, P. J., Sarna, S. J., & Taskinen, M. (2002) · Diabetes Care · doi:10.2337/diacare.25.10.1807 · Cited by 34 · see citing works
Self-citation
Is the fatty meal a trigger for acute coronary syndromes
Anderson, R. A., Jones, C. J. H., & Goodfellow, J. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(01)00669-4 · Cited by 33 · see citing works
Effect of heparin-stimulated plasma lipolytic activity on VLDL APO B subclass metabolism in normal subjects
Malmström, R., Packard, C. J., CASLAKE, M. J., Bedford, D. K., Stewart, P., Shepherd, J., & Taskinen, M. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)00153-7 · Cited by 32 · see citing works
Self-citation
Abnormalities of low density lipoproteins in normolipidemic type II diabetic and nondiabetic patients with coronary artery disease.
Tilly-Kiesi, M., Syvänne, M., Kuusi, T., Lahdenperä, S., & Taskinen, M. (1992) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41523-8 · Cited by 31 · see citing works
Self-citation
Enrichment with apolipoprotein E characterizes postprandial TG-rich lipoproteins in patients with non-insulin-dependent diabetes mellitus and coronary artery disease: a preliminary report
Syvänne, M., Rossened, M., Labeur, C., Hilden, H., & Taskinen, M. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)90004-3 · Cited by 28 · see citing works
Self-citation
Genetic determinants of plasma triglycerides: impact of rare and common mutations
Talmud, P. J. (2001) · Current Atherosclerosis Reports · doi:10.1007/s11883-001-0061-4 · Cited by 27 · see citing works
Transvascular Low-Density Lipoprotein Transport in Patients With Diabetes Mellitus (Type 2)
Kornerup, K., Nordestgaard, B. G., Feldt‐Rasmussen, B., Borch‐Johnsen, K., Jensen, K. S., & Jensen, J. S. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000022849.26083.fa · Cited by 27 · see citing works
Apolipoprotein C in Type 2 (non-insulin-dependent) diabetic patients with hypertriglyceridaemia
Stalenhoef, A. F. H., Demacker, P. N. M., Lutterman, J. A., & Laar, A. V. (1982) · Diabetologia · doi:10.1007/bf00282597 · Cited by 23 · see citing works
Composition of LDL as determinant of its susceptibility to in vitro oxidation in patients with well‐controlled type 2 diabetes
Scheffer, P. G., Bakker, S. J. L., Popp‐Snijders, C., Heine, R. J., Schutgens, R. B. H., & Teerlink, T. (2001) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.231 · Cited by 20 · see citing works
Increased ABCA1 activity protects against atherosclerosis
Singaraja, R. R., Fiévet, C., Castro, G. R., James, E. R., Hennuyer, N., Clee, S. M., Bissada, N., Choy, J. C., Fruchart, J., McManus, B. M., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215748 · Cited by 19 · see citing works
Composition of very-low-density lipoproteins in non-insulin-dependent diabetes mellitus.
Ishibashi, S., Yamada, N., Shimano, H., Takaku, F., Akanuma, Y., & Murase, T. (1989) · Clinical Chemistry · doi:10.1093/clinchem/35.5.808 · Cited by 12 · see citing works
Triglycerides and endothelial function in type 2 diabetes
Rongen, G. A. P. J. M., & Tack, C. J. (2001) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2001.00854.x · Cited by 9 · see citing works
Coronary heart disease in patients with low LDL-cholesterol. Benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors
Sacks, F. M., Tonkin, A. M., & Craven, T. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00773-0 · Cited by 9 · see citing works
Triglyceride-Rich Lipoproteins from Subjects with Type 2 Diabetes Do Not Demonstrate Increased Binding to Biglycan, a Vascular Proteoglycan
Tannock, L. R., Olin, K. L., Barrett, P. H. R., Wight, T. N., & Chait, A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.1.8190 · Cited by 8 · see citing works

Flagged first, then by citations

Sorted by citations

Pathophysiology of type 2 diabetes mellitus
Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., Ostolaza, H., & Martín, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176275 · Cited by 3,360 · see citing works
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67667-2 · Cited by 3,284 · see citing works
Pathophysiology of human visceral obesity: an update
Tchernof, A., & Després, J.-P. (2013) · Physiological Reviews · doi:10.1152/physrev.00033.2011 · Cited by 2,583 · see citing works
Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes
Monnier, L., Mas, E., Ginet, C., Michel, F., Villon, L., Cristol, J.-P., & Colette, C. (2006) · JAMA · doi:10.1001/jama.295.14.1681 · Cited by 2,444 · see citing works
Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research
Leon, B. M. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i13.1246 · Cited by 1,215 · see citing works
Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus
Tangvarasittichai, S. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i3.456 · Cited by 1,236 · see citing works
Clinical Update: Cardiovascular Disease in Diabetes Mellitus
Wang, C. C. L., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,183 · see citing works
Dyslipidemia in type 2 diabetes mellitus
Mooradian, A. D. (2009) · Nature Reviews Endocrinology · doi:10.1038/ncpendmet1066 · Cited by 1,053 · see citing works
Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome
Adiels, M., Olofsson, S.-O., Taskinen, M.-R., & Borén, J. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.160192 · Cited by 820 · see citing works
Self-citation
HDL and Reverse Cholesterol Transport: Basic Mechanisms and their Roles in Vascular Health and Disease
Ouimet, M., Barrett, T. J., & Fisher, E. (2019) · Circulation Research · doi:10.1161/circresaha.119.312617 · Cited by 416 · see citing works
Pathophysiology of diabetic dyslipidaemia: where are we?
Vergès, B. (2015) · Diabetologia · doi:10.1007/s00125-015-3525-8 · Cited by 708 · see citing works
Overproduction of large VLDL particles is driven by increased liver fat content in man
Adiels, M., Taskinen, M.-R., Packard, C., Caslake, M. J., Soro-Paavonen, A., Westerbacka, J., Vehkavaara, S., Häkkinen, A., Olofsson, S.-O., Yki-Järvinen, H., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0125-z · Cited by 690 · see citing works
Self-citation
Increased oxidative stress in obesity: Implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer
Matsuda, M., & Shimomura, I. (2013) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2013.05.004 · Cited by 642 · see citing works
American Association of Clinical Endocrinologists and American College of Endocrinology – Clinical Practice Guidelines for Developing A Diabetes Mellitus Comprehensive Care Plan – 2015 — Executive Summary
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G. E., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S. E., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 631 · see citing works
Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
Di Pino, A., & DeFronzo, R. A. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00141 · Cited by 535 · see citing works
Pathophysiology of Diabetic Dyslipidemia
Hirano, T. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17023 · Cited by 552 · see citing works
American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559 · see citing works
Causes and Metabolic Consequences of Fatty Liver
Stefan, N., Kantartzis, K., & Häring, H. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0009 · Cited by 527 · see citing works
Regulation of Plasma Triglycerides in Insulin Resistance and Diabetes
Ginsberg, H. N., Zhang, Y.-L., & Hernandez-Ono, A. (2005) · Archives of Medical Research · doi:10.1016/j.arcmed.2005.01.005 · Cited by 531 · see citing works
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan
Handelsman, Y., Mechanick, J. I., Blonde, L., Grunberger, G., Bloomgarden, Z. T., Bray, G. A., Dagogo-Jack, S., Davidson, J. A., Einhorn, D., Ganda, O., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.s2.1 · Cited by 513 · see citing works
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507 · see citing works
New insights into the pathophysiology of dyslipidemia in type 2 diabetes
Taskinen, M.-R., & Borén, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.039 · Cited by 440 · see citing works
Self-citation
Diabetes Dyslipidemia
Schofield, J. D., Liu, Y., Rao‐Balakrishna, P., Malik, R. A., & Soran, H. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0167-x · Cited by 423 · see citing works
Purified Anthocyanin Supplementation Reduces Dyslipidemia, Enhances Antioxidant Capacity, and Prevents Insulin Resistance in Diabetic Patients1–3
Li, D., Zhang, Y., Liu, Y., Sun, R., & Xia, M. (2015) · Journal of Nutrition · doi:10.3945/jn.114.205674 · Cited by 373 · see citing works
Diabetes and lipid metabolism
Athyros, V. G., Doumas, M. N., Imprialos, K. P., Stavropoulos, K., Georgianou, E., Katsimardou, A., & Karagiannis, A. I. (2018) · HORMONES · doi:10.1007/s42000-018-0014-8 · Cited by 373 · see citing works
American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm—2023 update
Samson, S. L., Vellanki, P., Blonde, L., Christofides, E. A., Galindo, R. J., Hirsch, I. B., Isaacs, S. D., Izuora, K. E., Low Wang, C. C., Twining, C. L., et al. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.02.001 · Cited by 375 · see citing works
SNARE proteins mediate fusion between cytosolic lipid droplets and are implicated in insulin sensitivity
Boström, P., Andersson, L. K., Rutberg, M., Perman, J., Lidberg, U., Johansson, B. R., Fernández-Rodrı́guez, J., Ericson, J., Nilsson, T., Borén, J., et al. (2007) · Nature Cell Biology · doi:10.1038/ncb1648 · Cited by 359 · see citing works
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes
Matikainen, N., Mänttäri, S., Schweizer, A., Ulvestad, A., Mills, D., Dunning, B. E., Foley, J. E., & Taskinen, M.-R. (2006) · Diabetologia · doi:10.1007/s00125-006-0340-2 · Cited by 336 · see citing works
Self-citation
Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia
Borén, J., Taskinen, M.-R., Björnson, E., & Packard, C. J. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00676-y · Cited by 315 · see citing works
Self-citation
Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis
Olofsson, S. ‐., & Borén, J. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01556.x · Cited by 328 · see citing works
Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study
Pradhan, A. D., Paynter, N. P., Everett, B. M., Glynn, R. J., Amarenco, P., Elam, M., Ginsberg, H., Hiatt, W. R., Ishibashi, S., Koenig, W., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.09.011 · Cited by 319 · see citing works
Lipid and lipoprotein dysregulation in insulin resistant states
Avramoglu, R. K., Basciano, H., & Adeli, K. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.12.026 · Cited by 318 · see citing works
Alterations in high‐density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins
Borggreve, S. E., Vries, R. D., & Dullaart, R. P. F. (2003) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2003.01263.x · Cited by 277 · see citing works
Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans
Meier, J. J., Gethmann, A., Götze, O., Gallwitz, B., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2006) · Diabetologia · doi:10.1007/s00125-005-0126-y · Cited by 276 · see citing works
Overproduction of VLDL 1 Driven by Hyperglycemia Is a Dominant Feature of Diabetic Dyslipidemia
Adiels, M., Borén, J., CASLAKE, M. J., Stewart, P., Soro, A., Westerbacka, J., Wennberg, B., Olofsson, S., Packard, C. J., & Taskinen, M. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000172689.53992.25 · Cited by 270 · see citing works
Self-citation
Lipid droplets as dynamic organelles connecting storage and efflux of lipids
Olofsson, S., Boström, P., Andersson, L. K., Rutberg, M., Perman, J., & Borén, J. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2008.08.001 · Cited by 264 · see citing works
Obesity and dyslipidemia
Franssen, R., Monajemi, H., Stroes, E. S. G., & Kastelein, J. J. P. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2011.06.003 · Cited by 270 · see citing works
Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C*
Chapman, M. J., Assmann, G., Fruchart, J., Shepherd, J., & Sirtori, C. R. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125004402 · Cited by 255 · see citing works
Intracellular Trafficking and Secretion of VLDL
Tiwari, S., & Siddiqi, S. A. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.241471 · Cited by 257 · see citing works
Mechanisms of Disease: adipocytokines and visceral adipose tissue—emerging role in nonalcoholic fatty liver disease
Schäffler, A., Schölmerich, J., & Büchler, C. (2005) · Nature Clinical Practice Gastroenterology &#38 Hepatology · doi:10.1038/ncpgasthep0186 · Cited by 240 · see citing works
Insulin resistance in type 1 diabetes: what is ‘double diabetes’ and what are the risks?
Cleland, S. J., Fisher, B. M., Colhoun, H. M., Sattar, N. A., & Petrie, J. R. (2013) · Diabetologia · doi:10.1007/s00125-013-2904-2 · Cited by 243 · see citing works
PPAR-α as a Key Nutritional and Environmental Sensor for Metabolic Adaptation
Contreras, A. V., Torres, N., & Tovar, A. R. (2013) · Advances in Nutrition · doi:10.3945/an.113.003798 · Cited by 237 · see citing works
Ectopic lipid storage and insulin resistance: a harmful relationship
Borén, J., Taskinen, M., Olofsson, S. ‐., & Levin, M. C. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12071 · Cited by 234 · see citing works
Self-citation
Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia
Nob�court, E., Jacqueminet, S., Hansel, B., Chantepie, S., Grimaldi, A., Chapman, M. J., & Kontush, A. (2005) · Diabetologia · doi:10.1007/s00125-004-1655-5 · Cited by 218 · see citing works
The role and function of HDL in patients with diabetes mellitus and the related cardiovascular risk
Femlak, M., Gluba-Brzózka, A., Ciałkowska-Rysz, A. D., & Rysz, J. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0594-3 · Cited by 222 · see citing works
Glucagon-Like Peptide-2 Increases Intestinal Lipid Absorption and Chylomicron Production via CD36
Hsieh, J., Longuet, C., Maida, A., Bahrami, J., Xu, E., Baker, C. L., Brubaker, P. L., Drucker, D. J., & Adeli, K. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.05.051 · Cited by 216 · see citing works
Cardiovascular metabolic syndrome – an interplay of, obesity, inflammation, diabetes and coronary heart disease
Rana, J. S., Nieuwdorp, M., Jukema, J. W., & Kastelein, J. J. P. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00594.x · Cited by 209 · see citing works
Lipoprotein abnormalities and their consequences for patients with type 2 diabetes
Krentz, A. J. (2003) · Diabetes Obesity and Metabolism · doi:10.1046/j.1462-8902.2003.0310.x · Cited by 205 · see citing works
Nobiletin Attenuates VLDL Overproduction, Dyslipidemia, and Atherosclerosis in Mice With Diet-Induced Insulin Resistance
Mulvihill, E. E., Assini, J. M., Lee, J. K., Allister, E. M., Sutherland, B. G., Koppes, J. B., Sawyez, C. G., Edwards, J. Y., Telford, D. E., Charbonneau, A., et al. (2011) · Diabetes · doi:10.2337/db10-0589 · Cited by 202 · see citing works
Hypertriglyceridemia secondary to obesity and diabetes
Subramanian, S., & Chait, A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.003 · Cited by 200 · see citing works
Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance
Adiels, M., Westerbacka, J., Soro‐Paavonen, A., Häkkinen, A. ‐., Vehkavaara, S., CASLAKE, M. J., Packard, C. J., Olofsson, S.-O., Yki‐Järvinen, H., Taskinen, M., et al. (2007) · Diabetologia · doi:10.1007/s00125-007-0790-1 · Cited by 197 · see citing works
Self-citation
Influence of Hepatic Steatosis (Fatty Liver) on Severity and Composition of Dyslipidemia in Type 2 Diabetes
Toledo, F. G. S., Sniderman, A. D., & Kelley, D. E. (2006) · Diabetes Care · doi:10.2337/dc06-0455 · Cited by 196 · see citing works
Lipid profile abnormalities seen in T2DM patients in primary healthcare in Turkey: a cross-sectional study
Özder, A. (2014) · Lipids in Health and Disease · doi:10.1186/1476-511x-13-183 · Cited by 187 · see citing works
Up-regulation of PPARγ, heat shock protein-27 and -72 by naringin attenuates insulin resistance, β-cell dysfunction, hepatic steatosis and kidney damage in a rat model of type 2 diabetes
Sharma, A. K., Bharti, S., Ojha, S. K., Bhatia, J., Kumar, N., Ray, R., Kumari, S., & Arya, D. S. (2011) · British Journal Of Nutrition · doi:10.1017/s000711451100225x · Cited by 185 · see citing works
Targeting fatty acid metabolism to improve glucose metabolism
Stinkens, R., Goossens, G. H., Jocken, J. W. E., & Blaak, E. E. (2015) · Obesity Reviews · doi:10.1111/obr.12298 · Cited by 183 · see citing works
Apolipoprotein C-III: from pathophysiology to pharmacology
Norata, G. D., Tsimikas, S., Pirillo, A., & Catapano, A. L. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.07.001 · Cited by 182 · see citing works
Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels
Marcovina, S. M., & Packard, C. J. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01648.x · Cited by 180 · see citing works
PLD1 and ERK2 regulate cytosolic lipid droplet formation
Andersson, L. K., Boström, P., Ericson, J., Rutberg, M., Magnusson, B., Marchesan, D., Ruiz, M., Asp, L., Huang, P. C., Frohman, M. A., et al. (2006) · Journal of Cell Science · doi:10.1242/jcs.02941 · Cited by 175 · see citing works
High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease
Rohrer, L., Hersberger, M., & von Eckardstein, A. (2004) · Current Opinion in Lipidology · doi:10.1097/00041433-200406000-00006 · Cited by 175 · see citing works
Beyond Low-Density Lipoprotein
Nesto, R. W. (2005) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200505060-00005 · Cited by 175 · see citing works
Diabetic dyslipidaemia
Adiels, M., Olofsson, S., Taskinen, M., & Borén, J. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000226115.97436.c0 · Cited by 172 · see citing works
Self-citation
Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD
Bril, F., Sninsky, J. J., Baca, A. M., Superko, H. R., Portillo-Sánchez, P., Biernacki, D., Maximos, M., Lomonaco, R., Orsak, B., Suman, A., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3111 · Cited by 168 · see citing works
Prevention and Treatment of Obesity, Insulin Resistance, and Diabetes by Bile Acid–Binding Resin
Kobayashi, M., Ikegami, H., Fujisawa, T., Nojima, K., Kawabata, Y., Noso, S., Babaya, N., Itoi‐Babaya, M., Yamaji, K., Hiromine, Y., et al. (2006) · Diabetes · doi:10.2337/db06-0353 · Cited by 167 · see citing works
Metabolic Dyslipidemia and Cardiovascular Outcomes in Type 2 Diabetes Mellitus: Findings From the Look AHEAD Study
Kazé, A. D., Santhanam, P., Musani, S. K., Ahima, R. S., & Echouffo-Tcheugui, J. B. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.016947 · Cited by 167 · see citing works
Relationship between Serum Lipoprotein Ratios and Insulin Resistance in Obesity
Brehm, A., Pfeiler, G., Pacini, G., Vierhapper, H., & Roden, M. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.037556 · Cited by 169 · see citing works
Insulin signaling to hepatic lipid metabolism in health and disease
Leavens, K. F., & Birnbaum, M. J. (2011) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2011.562481 · Cited by 162 · see citing works
Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen General Population Study
Langsted, A., & Nordestgaard, B. G. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.157164 · Cited by 160 · see citing works
Is Atherosclerosis in Diabetes and Impaired Fasting Glucose Driven by Elevated LDL Cholesterol or by Decreased HDL Cholesterol?
Drexel, H., Aczél, S., Marte, T., Benzer, W., Langer, P. H., Moll, W., & Saely, C. H. (2005) · Diabetes Care · doi:10.2337/diacare.28.1.101 · Cited by 161 · see citing works
The role of remnant cholesterol beyond low-density lipoprotein cholesterol in diabetes mellitus
Hu, X., Liu, Q., Guo, X., Wang, W., Yu, B., Liang, B., Zhou, Y., Dong, H., & Lin, J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01554-0 · Cited by 158 · see citing works
Serum triglycerides and risk of cardiovascular disease
Boullart, A. C. I., Graaf, J. D., & Stalenhoef, A. F. H. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.002 · Cited by 157 · see citing works
Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells
Abderrahmani, A., Niederhäuser, G., Favre, D., Abdelli, S., Ferdaoussi, M., Yang, J. Y., Regazzi, R., Widmann, C., & Waeber, G. (2007) · Diabetologia · doi:10.1007/s00125-007-0642-z · Cited by 147 · see citing works
Utility of Non-High-Density Lipoprotein Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Evaluating Incident Diabetes Risk
Sheng, G., Liu, D., Kuang, M., Zhong, Y., Zhang, S., & Zou, Y. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s355980 · Cited by 147 · see citing works
Fatty liver, insulin resistance, and dyslipidemia
Adiels, M., Taskinen, M., & Borén, J. (2008) · Current Diabetes Reports · doi:10.1007/s11892-008-0011-4 · Cited by 146 · see citing works
Self-citation
Liraglutide suppresses postprandial triglyceride and apolipoprotein <scp>B48</scp> elevations after a fat‐rich meal in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled, cross‐over trial
Hermansen, K., Bækdal, T. A., Düring, M., Pietraszek, A., Mortensen, L. S., Jørgensen, H., & Flint, A. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12133 · Cited by 143 · see citing works
SREBP-1 is an independent prognostic marker and promotes invasion and migration in breast cancer
Bao, J., Zhu, L., Zhu, Q., Su, J., Liu, M., & Huang, W. (2016) · Oncology Letters · doi:10.3892/ol.2016.4988 · Cited by 143 · see citing works
Triglycerides and Cardiovascular Risk
Harchaoui, K. E., Visser, M., Kastelein, J. J. P., Stroes, E. S. G., & Dallinga‐Thie, G. M. (2009) · Current Cardiology Reviews · doi:10.2174/157340309788970315 · Cited by 139 · see citing works
SREBP-1 Has a Prognostic Role and Contributes to Invasion and Metastasis in Human Hepatocellular Carcinoma
Li, C., Yang, W., Zhang, J., Zheng, X. M., Yao, Y., Tu, K., & Liu, Q. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15057124 · Cited by 138 · see citing works
One-year treatment with exenatide vs. Insulin Glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress
Bunck, M. C., Cornér, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Wu, Y., Yan, P., Smith, U., Yki-Järvinen, H., Diamant, M., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.04.024 · Cited by 132 · see citing works
Self-citation
Renal Lipid Metabolism and Lipotoxicity in Diabetes
Thongnak, L., Pongchaidecha, A., & Lungkaphin, A. (2019) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2019.11.004 · Cited by 132 · see citing works
Intestinal Insulin Resistance and Aberrant Production of Apolipoprotein B48 Lipoproteins in an Animal Model of Insulin Resistance and Metabolic Dyslipidemia
Federico, L. M., Naples, M., Taylor, D., & Adeli, K. (2006) · Diabetes · doi:10.2337/db04-1084 · Cited by 132 · see citing works
Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease
Packard, C. J. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000236367.42755.c1 · Cited by 127 · see citing works
Mobile health (<scp>mHealth</scp>) based medication adherence measurement – a pilot trial using electronic blisters in diabetes patients
Brath, H., Morak, J., Kästenbauer, T., Modre‐Osprian, R., Strohner‐Kästenbauer, H., Schwarz, M., Kort, W., & Schreier, G. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12184 · Cited by 121 · see citing works
Gut-liver interaction in triglyceride-rich lipoprotein metabolism
Xiao, C., Hsieh, J., Adeli, K., & Lewis, G. F. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00178.2011 · Cited by 126 · see citing works
Cardiovascular risk in women with diabetes
Rivellese, A. A., Riccardi, G., & Vaccaro, O. (2010) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2010.01.008 · Cited by 125 · see citing works
New insight into the pathophysiology of lipid abnormalities in type 2 diabetes
Vergès, B. L. (2005) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70213-6 · Cited by 126 · see citing works
Glycation of paraoxonase‐1 inhibits its activity and impairs the ability of high‐density lipoprotein to metabolize membrane lipid hydroperoxides
Mastorikou, M., Mackness, B., Liu, Y., & Mackness, M. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02546.x · Cited by 122 · see citing works
Increased Glycation and Oxidative Damage to Apolipoprotein B100 of LDL Cholesterol in Patients With Type 2 Diabetes and Effect of Metformin
Rabbani, N., Chittari, M. V., Bodmer, C. W., Zehnder, D., Ceriello, A., & Thornalley, P. J. (2010) · Diabetes · doi:10.2337/db09-1455 · Cited by 122 · see citing works
Herbal or Natural Medicines as Modulators of Peroxisome Proliferator‐Activated Receptors and Related Nuclear Receptors for Therapy of Metabolic Syndrome
Huang, T. H.-W., Kota, B. P., Razmovski, V., & Roufogalis, B. D. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto960102.x · Cited by 121 · see citing works
GLP-1 and GLP-2 as Yin and Yang of Intestinal Lipoprotein Production
Hein, G. J., Baker, C., Hsieh, J., Farr, S., & Adeli, K. (2012) · Diabetes · doi:10.2337/db12-0202 · Cited by 121 · see citing works
Dyslipidemia, but not hyperglycemia and insulin resistance, is associated with marked alterations in the HDL lipidome in type 2 diabetic subjects in the DIWA cohort: Impact on small HDL particles
Ståhlman, M., Fagerberg, B., Adiels, M., Ekroos, K., Chapman, J., Kontush, A., & Borén, J. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.07.009 · Cited by 120 · see citing works
Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial
Fadini, G. P., Bonora, B. M., Zatti, G., Vitturi, N., Iori, E., Marescotti, M. C., Albiero, M., & Avogaro, A. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0529-3 · Cited by 119 · see citing works
Helicobacter pyloriinfection and diabetes: Is it a myth or fact
He, C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i16.4607 · Cited by 118 · see citing works
Demystifying the management of hypertriglyceridaemia
Watts, G. F., Ooi, E. M. M., & Chan, D. C. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.140 · Cited by 115 · see citing works
Roles of Ceramides in Non-Alcoholic Fatty Liver Disease
Hajduch, É., Lachkar, F., Ferré, P., & Foufelle, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040792 · Cited by 113 · see citing works
Evaluation of loganin, iridoid glycoside from Corni Fructus, on hepatic and renal glucolipotoxicity and inflammation in type 2 diabetic db/db mice
Yamabe, N., Noh, J. S., Park, C. H., Kang, K. S., Shibahara, N., Tanaka, T., & Yokozawa, T. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.08.044 · Cited by 111 · see citing works
Dyslipidemias in the Prevention of Cardiovascular Disease: Risks and Causality
Graham, I. M., Cooney, M. T., Bradley, D., Dudina, A. L., & Reiner, Ž. (2012) · Current Cardiology Reports · doi:10.1007/s11886-012-0313-7 · Cited by 109 · see citing works
Paraoxonase-1 as a Regulator of Glucose and Lipid Homeostasis: Impact on the Onset and Progression of Metabolic Disorders
Meneses, M. J., Silvestre, R. D., Sousa‐Lima, I., & Macedo, M. P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20164049 · Cited by 114 · see citing works
Postprandial inflammation and endothelial dysfuction
Alipour, A., Elte, J. W. F., van Zaanen, H. C. T., Rietveld, A. P., & Cabezas, M. C. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350466 · Cited by 108 · see citing works
A 52-Week, Randomized, Open-Label, Parallel-Group Comparison of the Tolerability and Effects of Pitavastatin and Atorvastatin on High-Density Lipoprotein Cholesterol Levels and Glucose Metabolism in Japanese Patients with Elevated Levels of Low-Density Lipoprotein Cholesterol and Glucose Intolerance
Sasaki, J. D., Ikeda, Y., Kuribayashi, T., Kajiwara, K., Biro, S., Yamamoto, K., Ageta, M., Kobori, S., Saikawa, T., Otonari, T., et al. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.05.017 · Cited by 109 · see citing works
Apolipoprotein AI) Promotes Atherosclerosis Regression in Diabetic Mice by Suppressing Myelopoiesis and Plaque Inflammation
Barrett, T. J., Distel, E., Murphy, A. J., Hu, J., Garshick, M. S., Ogando, Y., Liu, J. J., Vaisar, T., Heinecke, J. W., Berger, J. S., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.039476 · Cited by 106 · see citing works

Diabetic dyslipidaemia
Adiels, M., Olofsson, S., Taskinen, M., & Borén, J. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000226115.97436.c0 · Cited by 172 · see citing works
Self-citation
Type 2 Diabetes as a Lipid Disorder
Taskinen, M. (2005) · Current Molecular Medicine · doi:10.2174/1566524053766086 · Cited by 135 · see citing works
Self-citation
Abnormal hepatic apolipoprotein B metabolism in type 2 diabetes
Vergès, B. L. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.01.028 · Cited by 95 · see citing works
Overproduction of VLDL 1 Driven by Hyperglycemia Is a Dominant Feature of Diabetic Dyslipidemia
Adiels, M., Borén, J., CASLAKE, M. J., Stewart, P., Soro, A., Westerbacka, J., Wennberg, B., Olofsson, S., Packard, C. J., & Taskinen, M. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000172689.53992.25 · Cited by 270 · see citing works
Self-citation
Mechanisms of Diabetic Dyslipidemia: Relevance for Atherogenesis
Arca, M., Pigna, G., & Favoccia, C. (2012) · Current Vascular Pharmacology · doi:10.2174/157016112803520864 · Cited by 100 · see citing works

Authors: Taskinen, M.-R.
Affiliations: University of Helsinki (FI)
Corresponding author: Taskinen, M.-R.
ORCID: Taskinen, M.-R.
Venue: Diabetologia
Publisher: Springer Science and Business Media LLC
Published: 2003-06-01
Volume: 46
Issue: 6
Pages: 733-749
ISSN: 0012-186X (ISSN-L)
1432-0428
DOI: 10.1007/s00125-003-1111-y
OpenAlex: W2020659754
Cited by: 888
References: 183
Citations by year: 2026: 27 · 2025: 37 · 2024: 32 · 2023: 36 · 2022: 48 · 2021: 41 · 2020: 39 · 2019: 27 · 2018: 32 · 2017: 28 · 2016: 29 · 2015: 47 · 2014: 41 · 2013: 46 · 2012: 42
FWCI: 6.10
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
Locations: Diabetologia (publishedVersion)
PubMed (publishedVersion)
Funders: Helsingin ja Uudenmaan Sairaanhoitopiiri
Academy of Finland
Diabetesliitto
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
Keywords: diabetic dyslipidemia, type 2 diabetes, small dense LDL, triglyceride-rich lipoproteins, VLDL assembly, hepatic lipid metabolism, insulin signaling, PI3-kinase, SREBP-1c, de novo lipogenesis, apolipoprotein B-100, peroxisome proliferator-activated receptors, SREBP1, liver X receptor
MeSH terms: Diabetes Mellitus, Diabetes Mellitus, Type 2, Humans, Hyperlipidemias, Lipoproteins, Lipoproteins, VLDL, Diabetes Complications, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Diabetic dyslipidaemia: from basic research to clinical practice*

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks